MetaCap

BridgeBio Pharma (BBIO) vs Spyre Therapeutics (SYRE)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Spyre Therapeutics (SYRE) has outperformed BridgeBio Pharma (BBIO) over the past year, gaining 285.3% versus a gain of 11.6%. Over five years, BBIO leads with a +92.2% price change compared with -42.0% for SYRE. BridgeBio Pharma is the larger company by market cap ($14.81 billion vs $8.88 billion), about 1.7 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BBIO+11.63%SYRE+285.28%
+367%+171%-25%
Nov 21, 20251 yearNov 20, 2026
BBIO+78.26%SYRE-44.03%
+111%+2%-108%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BBIO versus SYRE key metrics
MetricBBIOSYRE
Share price$76.03$93.47
Market cap$14.81B$8.88B
1-day change-2.75%-4.26%
YTD return-0.60%+185.32%
1-year return+11.63%+285.28%
5-year return+92.24%-42.03%
EPS (TTM)$-3.03$-2.49
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$502.08M$0
Revenue growth (YoY)+126.26%—
Net income (latest FY)$-732.94M$-155.20M
Gross margin95.82%—
Operating margin-104.25%—
Net margin-145.98%—
52-week high$93.42$110.64
52-week low$62.50$24.58
Distance from 52-week high-18.61%-15.52%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+40.73%+32.52%
Average volume2.67M1.26M
Shares outstanding194.80M94.97M
Employees1,081130
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • SYRE has outperformed BBIO by 273.7 percentage points over the past year.

About BridgeBio Pharma

BBIO stock →

BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 clinical stage or the treatment of children with achondroplasia and hypochondroplasia.

Health Care · Biotechnology: Pharmaceutical Preparations · 1,081 employees

About Spyre Therapeutics

SYRE stock →

Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 – anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A).

Health Care · Biotechnology: Pharmaceutical Preparations · 130 employees

BBIO vs SYRE FAQ

Which is bigger, BridgeBio Pharma or Spyre Therapeutics?

BridgeBio Pharma (BBIO) is larger, with a market capitalization of $14.81B compared with $8.88B for Spyre Therapeutics (SYRE).

Which stock has performed better over the past year, BBIO or SYRE?

SYRE returned +285.28% over the past 12 months, compared with +11.63% for BBIO (price return, excluding dividends). Past performance does not predict future results.

Are BridgeBio Pharma and Spyre Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons